BRIEF-Gemini reports Q1 net loss per share of $0.04
* Now expecting revenue for 2017 to be less than 2016 but expects activity to pick up in second half of 2017 into 2018 Source text for Eikon: Further company coverage:
May 15 Nuvo Pharmaceuticals Inc
* Nuvo Pharmaceuticals Inc announces topline results from European ankle sprain study with Pennsaid 2 pct
* Nuvo Pharmaceuticals Inc - trial had failed to meet its primary endpoint
* Nuvo Pharmaceuticals - will continue to assess opportunities available to pursue marketing authorizations for Pennsaid 2 pct in Canada, Australia and E.U.
* Nuvo Pharmaceuticals - will be reviewing trial results in with its scientific advisors and regulatory consultants to determine what its next steps should be Source text for Eikon: Further company coverage:
* Ironhorse announces Q1 2017 financial and operating results